DXCM DexCom, Inc.
USHealthcareAs of 2026-10-08
Why DXCM matters now
DexCom, Inc. (DXCM) is a US stock in Healthcare. The latest InvestLog snapshot shows $84.41 with +0.13% on the session and $31.85B in market capitalization; recent performance reads 1-month +8.24% and YTD +9.19%.
The latest financial table shown here is Q1 2026, with revenue of $1.19B, net income of $199.5M, and EPS of $0.51. Investors can compare that operating picture with valuation signals such as P/E 29.86 and FCF yield 5.1%.
InvestLog's latest related AI research is a Rating Change note titled "Barclays initiates coverage of DXCM with Overweight". The latest indexable market news headline is "Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $85.00; recent insider activity includes FOLETTA MARK G filing S-Sale; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
29.86
PEG
0.66
P/B
9.44
P/S
5.80
EV/EBITDA
19.13
DCF Value
$46.86
FCF Yield
5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.8%
Operating Margin
21.4%
Net Margin
19.3%
ROE
33.8%
ROA
14.0%
ROIC
18.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.19B | $199.5M | $0.51 |
| Q4 2025 | $1.26B | $267.3M | $0.68 |
| FY 2025 | $4.66B | $836.3M | $2.09 |
| Q3 2025 | $1.21B | $283.8M | $0.70 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$83.56
Target (Median)
$85.00
Target Range
$64.00 - $95.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Barclays initiates coverage of DXCM with OverweightBarclays 首次覆盖 德康医疗 (DXCM)，初始评级 增持（Overweight）
On 2026-10-06, Barclays initiated coverage of DXCM with a Overweight rating.Barclays 于 2026-10-06 首次覆盖 DXCM，初始评级为 增持（Overweight）。
RBC Capital raises DXCM target to $105 from $90RBC Capital 上调目标价 德康医疗 (DXCM)：$90 → $105
On 2026-10-01, RBC Capital raised its DXCM price target to $105 from $90 (+16.7%).RBC Capital 于 2026-10-01 将 DXCM 目标价上调至 $105，此前为 $90，变动幅度 +16.7%。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.44
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.